E.1 Afección o enfermedad investigada |
E.1.1 |
Medical condition(s) being investigated |
Geographic atrophy secondary to dry age-related macular degeneration |
Atrofia geográfica secundaria a la degeneración macular seca asociada con la edad. |
|
E.1.1.1 |
Medical condition in easily understood language |
Geographic atrophy secondary to dry age-related macular degeneration |
Atrofia geográfica secundaria a la degeneración macular seca asociada con la edad. |
|
E.1.1.2 |
Therapeutic area |
Diseases [C] – Eye Diseases [C11] |
MedDRA Classification |
E.1.2 Medical condition or disease under investigation |
E.1.2 |
Version |
20.0 |
E.1.2 |
Level |
PT |
E.1.2 |
Classification code |
10075567 |
E.1.2 |
Term |
Dry age-related macular degeneration |
E.1.2 |
System Organ Class |
10015919 – Eye disorders |
|
E.1.3 |
Condition being studied is a rare disease |
No |
E.2 Objective of the trial |
E.2.1 |
Main objective of the trial |
The objectives of this study are to evaluate the safety and efficacy of Zimura intravitreal administration in patients with geographic atrophy secondary to dry age-related macular degeneration (AMD) |
Los objetivos de este estudio son evaluar la seguridad y la eficacia de la administración intravítrea de Zimura en pacientes con atrofia geográfica secundaria a la degeneración macular asociada a la edad (DMAE) seca. |
|
E.2.2 |
Secondary objectives of the trial |
|
E.2.3 |
Trial contains a sub-study |
No |
E.3 |
Principal inclusion criteria |
Ophthalmic Inclusion Criteria
The following inclusion criteria apply to the study eye (SE):
– Non-foveal GA secondary to dry AMD.
– The atrophic lesion must be able to be photographed in its entirety.
– Best corrected visual acuity in the SE between 20/25 – 20/320, inclusive.General Inclusion Criteria
– Patients of either gender aged ≥ 50 years.
– Women must be using two forms of effective contraception, be postmenopausal for at least 12 months prior to trial entry, or surgically sterile; if of child-bearing potential, a serum pregnancy test must be performed within 14 days prior to the first injection with a negative result. The two forms of effective contraception must be implemented during the trial and for at least 60 days following the last dose of test medication.
– Provide written informed consent.
– Ability to return for all trial visits. |
Criterios de inclusión oftalmológicos:
Los siguientes criterios de inclusión corresponden al ojo en estudio (OE):
-AG no foveal secundaria a DMAE seca.
-La lesión atrófica debe poder fotografiarse en su totalidad.
-Mejor agudeza visual corregida en el OE entre 20/25-20/320, inclusiveCriterios generales de inclusión:
-Pacientes de ambos sexos de ≥50 años de edad.
-Las mujeres deben utilizar dos métodos anticonceptivos eficaces, encontrarse en la etapa posmenopáusica al menos en los 12 meses previos a la inclusión en el ensayo clínico o ser estériles quirúrgicamente. En caso de encontrarse en edad fértil, debe obtenerse un resultado negativo en una prueba de embarazo en suero realizada en los 14 días previos a la primera inyección. Los dos métodos anticonceptivos eficaces tienen que utilizarse durante la participación en el ensayo clínico y, como mínimo, durante los 60 días posteriores a la última dosis de la medicación en estudio
-Dar consentimiento informado por escrito.
-Capacidad para acudir a todas las visitas del estudio durante los 24 meses de duración del estudio. |
|
E.4 |
Principal exclusion criteria |
Patients will not be eligible for the trial if patients cannot attend all trial required visits, or if any of the following criteria are present systemically or in the SE:
Ophthalmic Exclusion Criteria
The following exclusion criteria apply to the SE:
Evidence of CNV in either eye.
– Any prior treatment for AMD (dry or wet) or any prior intravitreal treatment for any indication in either eye, except oral supplements of vitamins and minerals.
– Any ocular condition in the SE that would progress during the course of the study that could affect central vision or otherwise be a confounding factor.
– Presence of other causes of choroidal neovascularization
– Any intraocular surgery or thermal laser within 3 months of trial entry. Any prior thermal laser in the macular region, regardless of indication.
– Any ocular or periocular infection (including blepharitis), or ocular surface inflammation in the past 12 weeks.
– Any sign of diabetic retinopathy in either eye. |
Los pacientes no serán aptos para el ensayo si no pueden asistir a todas las visitas requeridas del ensayo o si alguno de los siguientes criterios está presente sistémicamente o en el OE:
Criterios de exclusión oftalmológicos
Los siguientes criterios de exclusión se aplican al OE:
-Indicios de neovascularización coroidea (NVC) en cualquier ojo.
-Cualquier tratamiento previo para la DMAE (seca o húmeda) o cualquier tratamiento intravítreo previo para cualquier indicación en cualquiera de los ojos, excepto complementos orales de vitaminas y minerales.
-Cualquier afección ocular en el OE que progrese durante el transcurso del estudio que podría afectar a la visión central o suponer un factor de confusión.
-Presencia de otras causas de neovascularización coroidea
-Cualquier intervención quirúrgica intraocular o procedimiento con láser térmico en los 3 meses previos a la inclusión en el estudio. Cualquier procedimiento previo con láser térmico en la región macular, con independencia de la indicación.
-Cualquier infección ocular o periocular (incluida blefaritis) o inflamación de la superficie ocular en las 12 semanas anteriores.
-Cualquier signo de retinopatía diabética en cualquier ojo. |
|
E.5 End points |
E.5.1 |
Primary end point(s) |
Primary Efficacy Endpoint:
Mean rate of change in GA over 12 months measured by FAF at three time points:
Baseline, Month 6, and Month 12 (square root transformation)Safety Endpoints:
• AEs
• Vital signs (pulse, systolic and diastolic blood pressure)
• Ophthalmic variables (BCVA, LLBCVA, IOP, and ophthalmic examination)
• ECG (12-lead)
• Laboratory variables (blood: hematology, renal function, hepatic function, and electrolytes; urinalysis) |
Criterio principal de valoración de la eficacia:
-Tasa media de cambio en la atrofia geográfica durante 12 meses medida por autofluorescencia del fondo de ojo (FAF) en tres momentos: Inicio, mes 6 y mes 12 (transformación cuadrática)Criterios de valoración de la seguridad:
-Acontecimientos adversos (AA)
-Constantes vitales (pulso, tensión arterial sistólica y diastólica)
-Hallazgos oftalmológicos (mejor agudeza visual corregida [MAVC], MAVC con baja luminosidad, presión intraocular [PIO] y exploración oftalmológica)
-Electrocardiograma (ECG) (12 derivaciones)
-Variables analíticas (sangre: hemograma, función renal, función hepática y electrolitos; análisis de orina) |
|
E.5.1.1 |
Timepoint(s) of evaluation of this end point |
Baseline, Month 6, and Month 12 |
Visita basal. mes 6 y mes 12 |
|
E.5.2 |
Secondary end point(s) |
|
E.5.2.1 |
Timepoint(s) of evaluation of this end point |
|
E.6 and E.7 Scope of the trial |
E.6 |
Scope of the trial |
E.6.1 |
Diagnosis |
No |
E.6.2 |
Prophylaxis |
No |
E.6.3 |
Therapy |
Yes |
E.6.4 |
Safety |
Yes |
E.6.5 |
Efficacy |
Yes |
E.6.6 |
Pharmacokinetic |
No |
E.6.7 |
Pharmacodynamic |
No |
E.6.8 |
Bioequivalence |
No |
E.6.9 |
Dose response |
No |
E.6.10 |
Pharmacogenetic |
No |
E.6.11 |
Pharmacogenomic |
No |
E.6.12 |
Pharmacoeconomic |
No |
E.6.13 |
Others |
No |
E.7 |
Trial type and phase |
E.7.1 |
Human pharmacology (Phase I) |
No |
E.7.1.1 |
First administration to humans |
No |
E.7.1.2 |
Bioequivalence study |
No |
E.7.1.3 |
Other |
No |
E.7.1.3.1 |
Other trial type description |
|
E.7.2 |
Therapeutic exploratory (Phase II) |
No |
E.7.3 |
Therapeutic confirmatory (Phase III) |
Yes |
E.7.4 |
Therapeutic use (Phase IV) |
No |
E.8 Design of the trial |
E.8.1 |
Controlled |
Yes |
E.8.1.1 |
Randomised |
Yes |
E.8.1.2 |
Open |
No |
E.8.1.3 |
Single blind |
No |
E.8.1.4 |
Double blind |
Yes |
E.8.1.5 |
Parallel group |
Yes |
E.8.1.6 |
Cross over |
No |
E.8.1.7 |
Other |
No |
E.8.2 |
Comparator of controlled trial |
E.8.2.1 |
Other medicinal product(s) |
No |
E.8.2.2 |
Placebo |
No |
E.8.2.3 |
Other |
Yes |
E.8.2.3.1 |
Comparator description |
Zimura y simulación administrada por un investigador desenmascarado |
Zimura and sham administered by an unmasked investigator |
|
E.8.2.4 |
Number of treatment arms in the trial |
2 |
E.8.3 |
The trial involves single site in the Member State concerned |
No |
E.8.4 |
The trial involves multiple sites in the Member State concerned |
Yes |
E.8.4.1 |
Number of sites anticipated in Member State concerned |
11 |
E.8.5 |
The trial involves multiple Member States |
Yes |
E.8.5.1 |
Number of sites anticipated in the EEA |
58 |
E.8.6 Trial involving sites outside the EEA |
E.8.6.1 |
Trial being conducted both within and outside the EEA |
Yes |
E.8.6.2 |
Trial being conducted completely outside of the EEA |
No |
E.8.6.3 |
If E.8.6.1 or E.8.6.2 are Yes, specify the regions in which trial sites are planned |
Argentina |
Australia |
Brazil |
Canada |
Colombia |
Croatia |
Czech Republic |
Estonia |
France |
Germany |
Hungary |
Israel |
Italy |
Latvia |
Poland |
Spain |
United Kingdom |
United States |
|
E.8.7 |
Trial has a data monitoring committee |
Yes |
E.8.8 |
Definition of the end of the trial and justification where it is not the last visit of the last subject undergoing the trial |
LVLS |
Ultima visita del ultimo sujeto |
|
E.8.9 Initial estimate of the duration of the trial |
E.8.9.1 |
In the Member State concerned years |
2 |
E.8.9.1 |
In the Member State concerned months |
|
E.8.9.1 |
In the Member State concerned days |
|
E.8.9.2 |
In all countries concerned by the trial years |
2 |